ILLUMINA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ILLUMINA, INC. (ILMN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $10.00 million for the 3-month period ending 2025-06-29, per its 10-Q filed 2025-08-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-08-01
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2025-06-29 was $10.00M, a 75.61% decline year-over-year.
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2025-03-30 was $10.00M, a 54.55% decline year-over-year.
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-12-29 was $42.00M.
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-09-29 was -$53.00M.
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $52.00M, a 39.53% decline from fiscal 2023.
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $86.00M, a 1.15% decline from fiscal 2023.
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $87.00M.
- ILLUMINA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|---|---|---|
| 2025-06-29 | $10.00M 10-Q · filed 2025-08-01 | $20.00M 10-Q · filed 2025-08-01 | $62.00M derived: sum of 3 quarters · filed 2025-08-01 | $9.00M derived: sum of 4 quarters · filed 2025-08-01 |
| 2025-03-30 | $10.00M 10-Q · filed 2025-05-09 | $52.00M derived: sum of 2 quarters · filed 2025-05-09 | -$1.00M derived: sum of 3 quarters · filed 2025-05-09 | $40.00M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-29 | $42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$11.00M derived: sum of 2 quarters · filed 2025-02-12 | $30.00M derived: sum of 3 quarters · filed 2025-02-12 | $52.00M 10-K · filed 2025-02-12 |
| 2024-09-29 | -$53.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$12.00M derived: sum of 2 quarters · filed 2024-11-06 | $10.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $41.00M 10-Q · filed 2024-08-07 | $63.00M 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $22.00M derived: 10-K 12 month − 3 quarters · filed 2025-02-12 | |||
| 2023-12-31 | $86.00M 10-K · filed 2025-02-12 | |||
| 2023-04-02 | $49.00M 10-Q · filed 2023-05-05 | $45.00M derived: sum of 2 quarters · filed 2025-02-12 | $109.00M derived: sum of 3 quarters · filed 2025-02-12 | $132.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-01-01 | -$4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $60.00M derived: sum of 2 quarters · filed 2025-02-12 | $83.00M derived: sum of 3 quarters · filed 2025-02-12 | $87.00M 10-K · filed 2025-02-12 |
| 2022-10-02 | $64.00M 10-Q · filed 2022-11-04 | $87.00M derived: sum of 2 quarters · filed 2022-11-04 | $91.00M 10-Q · filed 2022-11-04 | |
| 2022-07-03 | $23.00M 10-Q · filed 2022-08-11 | $27.00M 10-Q · filed 2022-08-11 | ||
| 2022-04-03 | $4.00M 10-Q · filed 2022-05-05 | |||
| 2022-01-02 | $0.00 10-K · filed 2024-02-16 | |||
| 2021-01-03 | $0.00 10-K · filed 2023-02-17 | |||
| 2012-12-30 | $137.00K 10-K · filed 2014-02-18 | |||
| 2012-01-01 | $1.99M 10-K · filed 2014-02-18 | |||
| 2011-01-02 | $517.00K 10-K · filed 2013-02-15 | |||
| 2010-01-03 | $4.39M 10-K · filed 2012-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WATERS CORP /DE/ (WAT) | United States | $42.297B | 224.28 |
| AGILENT TECHNOLOGIES, INC. (A) | United States | $48.720B | 27.14 |
| METTLER TOLEDO INTERNATIONAL INC/ (MTD) | $30.436B | 30.62 | |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |